Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial por Patrick M. Wieruszewski, Rinaldo Bellomo, Laurence W. Busse, Kealy R. Ham, Alexander Zarbock, Ashish K. Khanna, Adam M. Deane, Marlies Ostermann, Richard G. Wunderink, David W. Boldt, Stew Kroll, Chuck R. Greenfeld, Tony Hodges, Jonathan H. Chow, the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators

Obter o texto integral